Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corcept Therapeutics Inc. (CORT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain their contents. Corcept is a Nasdaq-listed, commercial-stage pharmaceutical company focused on cortisol modulation in endocrinologic, oncologic, metabolic and neurologic disorders, and its filings offer detailed insight into this business.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Corcept describes its commercial activities with Korlym, which it identifies as the first FDA-approved medication for patients with endogenous hypercortisolism, as well as its research and development programs in hypercortisolism, solid tumors, ALS and liver disease. These periodic reports typically discuss product revenue, research and development spending, and risks related to drug development and regulation.
Current reports on Form 8-K, some of which are summarized in the data provided, disclose material events such as quarterly financial results, submission and FDA acceptance of New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application to the European Medicines Agency, and the receipt of an FDA Complete Response Letter for relacorilant in hypertension secondary to hypercortisolism. Other 8-K filings describe corporate developments, including changes to distribution agreements for Korlym and board-level changes accompanied by consulting arrangements.
On this page, users can review Corcept’s Forms 10-K, 10-Q and 8-K as they are made available from EDGAR, while AI-generated highlights point out key topics such as clinical trial updates, regulatory milestones, revenue trends and significant contracts. The filings section also surfaces exhibits referenced in 8-Ks, helping investors and researchers understand how Corcept’s cortisol-modulation strategy, pipeline progress and commercial operations are reflected in its official regulatory reporting.
Gillian M. Cannon, a director of Corcept Therapeutics Inc. (CORT), reported a donation of 7,393 shares of the issuer's common stock executed on 09/10/2025 under transaction code G(1). The filing shows the shares were donated to a Fidelity Charitable Giving Account and the reporting person’s beneficial ownership of common stock following the transaction is reported as 0 shares. The Form 4 was signed by an attorney-in-fact, Joseph Douglas Lyon, on 09/11/2025. The filing includes a remark that the power of attorney is on file with the SEC.
Daniel N. Swisher Jr., a director of Corcept Therapeutics, executed transactions on 09/10/2025 under a 10b5-1 plan adopted August 1, 2024. He exercised 2,200 stock options with an exercise price of $14.08 and simultaneously sold the resulting 2,200 common shares at $72.45. Following the transactions, the Form 4 reports 0 shares of common stock beneficially owned from the sold shares. The filing also shows the exercised options were fully exercisable and references remaining derivative holdings totaling 3,300 (as reported in the derivative table). The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Form 144 notice for Corcept Therapeutics, Inc. (CORT) discloses a proposed sale of 2,200 common shares to be executed on 09/10/2025 through Fidelity Brokerage Services (NASDAQ). The filing lists an aggregate market value of $159,390 and reports 105,371,729 shares outstanding. The shares were acquired under an option granted 08/20/2018 and the reported payment method is cash. The filer, identified in past sales as Daniel Swisher, sold three prior blocks of 2,200 shares each on 06/10/2025, 07/10/2025 and 08/11/2025, with gross proceeds shown for each sale. Remarks and signature attestations are present but no additional explanatory text or plan-adoption date is provided.
Gillian M. Cannon, a director of Corcept Therapeutics (CORT), executed option activity on 09/04/2025. She exercised 11,000 stock options at an exercise price of $22.99 per share and received 11,000 shares. To cover the exercise cost in a net (cashless) exercise, 3,607 shares were withheld at an implied price of $70.13, leaving 7,393 shares issued to her from that portion. Following these transactions, the filing reports 11,000 common shares directly owned from the exercise and 49,000 derivative securities (stock options) beneficially owned and fully exercisable through their stated expiration date of 12/01/2030.
William Guyer, Chief Development Officer of Corcept Therapeutics (CORT), reported multiple transactions dated 09/02/2025. The filing shows an acquisition of 20,000 common shares and contemporaneous sales of 15,594 and 4,406 common shares at weighted-average prices of $70.392 and $70.8478, respectively, for total shares sold of 20,000. The sales were made pursuant to a 10b5-1 trading plan adopted on 11/27/2024. The report also records a transaction in a derivative security: 20,000 stock options with a $21.65 exercise/conversion price and noted as fully exercisable, and the filing indicates 330,000 derivative securities beneficially owned following the transaction. Following these trades, Mr. Guyer beneficially owns 25,487 common shares directly.
Corcept Therapeutics (CORT) insider Joseph D. Lyon, Chief Accounting & Technology Officer, reported multiple transactions on 09/02/2025 and 09/03/2025. He exercised a stock option with a $13.56 strike for 5,000 shares on 09/02/2025, increasing derivative-based beneficial ownership to 26,571 shares. On the same day he sold a total of 5,000 shares under a 10b5-1 plan (weighted average sale prices noted at $70.2386 and $70.7571), purchased 200 shares under the company Purchase Plan at the closing price ($71.38), received 200 restricted shares at $0 under the Purchase Plan, and had 189 shares withheld to satisfy tax withholding upon vesting. The reporting person adopted the 10b5-1 plan on 08/30/2024. All reported holdings are direct.
Sean Maduck, President of Corcept Endocrinology, reported multiple transactions in Corcept Therapeutics (CORT) on 09/02/2025 and 09/03/2025. He exercised options to acquire 20,000 shares at $5.05 on 09/02/2025 and immediately sold portions under a 10b5-1 plan, selling 15,070 shares at a weighted average price of $70.3787 and 4,930 shares at a weighted average price of $70.8359. He purchased 228 shares under the company Purchase Plan at a closing price and received 228 restricted shares (zero price) that vest in one year. The report discloses indirect holdings via trusts and an LLC and shows tax-withheld shares upon vesting.
Joseph K. Belanoff, Chief Executive Officer and a director of Corcept Therapeutics, reported two open-market sales under a Rule 10b5-1 trading plan on 09/02/2025. The filing discloses a sale of 39,300 shares at a weighted average price of $70.5172 and a separate sale of 700 shares at a weighted average price of $71.0107. After the sales the reported beneficial ownership figures shown in the form are 2,822,070 shares and 2,821,370 shares, held indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which the reporting person states he has voting power but disclaims beneficial ownership except for his pecuniary interest. The transactions were made pursuant to a 10b5-1 plan adopted November 26, 2024.
Corcept Therapeutics (CORT) reporting person Atabak Mokari, the company's Chief Financial Officer, executed purchases and experienced withholding tied to restricted stock vesting in early September 2025. On 09/02/2025 the Reporting Person purchased 200 shares under a Purchase Plan at a price established by that day's closing price ($71.38), and was also granted 200 Purchase Plan shares recorded at $0.00. On 09/03/2025 the issuer withheld 144 shares to satisfy tax-withholding obligations related to the vesting of restricted stock units. The filing states the Reporting Person beneficially owned 14,321 shares following these transactions and discloses 231, 232, and 775 shares underlying unvested restricted stock awards that vest 100% on the one-year anniversary of their grant dates if conditions are met.